Product Description
Transferrin Receptor (Extracellular domain) Antibody [TFRC/1818] | 33-825 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: Amino acids 94-212 (extracellular domain) of the human protein were used as the immunogen for the Transferrin Receptor antibody.
Research Area: Cancer, Immunology, Obesity, Signal Transduction
Tested Application: Flow, IF, IHC-P, E, WB
Application: WB: 0.5-1 ug/ml
ELISA: 2-4 ug/ml; order the BSA free formulation for coating
Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 1-2 ug/ml
IHC (FFPE) : 1-2 ug/ml for 30 min at RT
Optimal dilution of the Transferrin Receptor antibody should be determined by the researcher.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein G affinity chromatography
Clonality: Monoclonal
Clone: TFRC/1818
Isotype: IgG2b, kappa
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: Transferrin receptor protein 1, TR, TfR, TfR1, Trfr, T9, p90, CD71, Transferrin receptor protein 1, serum form, sTfR, TFRC
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: It recognizes a ~85-95kDa protein which is identified as cell surface transferrin receptor (CD71) , a disulfide-bonded homodimeric glycoprotein of 180-190kDa. This mAb is highly specific to Transferrin Receptor / CD71 and shows no cross-reaction with other related proteins. Ligand for transferrin receptor is the serum iron transport protein, transferrin. This receptor is broadly distributed in carcinomas, sarcomas, leukemias, and lymphomas. CD71/Transferrin Receptor has been reported to be associated with cell proliferation in both normal and neoplastic tissues and useful in predicting clinical behavior or response to therapy in a number of malignancies including breast cancer.